Efficacy and safety of canagliflozin in type 2 diabetes patients of different ethnicity

Ethnicity and Disease

Volumn 26, Issue 2, 2016, Pages 221-228

  Davidson, Jaime A ^a   Aguilar, Richard ^b   González, Fernando J Lavalle ^c   Trujillo, Angelina ^d   Alba, Maria ^d   Vijapurkar, Ujjwala ^d   Meininger, Gary ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Seville Medical Center   (United States)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Canagliflozin; Efficacy; Glucose Cotransporter Inhibitor; Hispanic; Latino; Safety; Type 2 Diabetes Mellitus

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; LIPID; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; VAGINA MYCOSIS; AGED; BLOOD PRESSURE; ETHNOLOGY; META ANALYSIS; MIDDLE AGED; MYCOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964986253     PISSN: 1049510X     EISSN: 19450826     Source Type: Journal    
DOI: 10.18865/ed.26.2.221     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014: Estimates of Diabetes and Its Burden in the United States. Available from: http://www.cdc.gov/ diabetes/pubs/statsreport14/national-diabetesreport-web.pdf. Accessed January 12, 2015.
2. American Diabetes Association. Fast Facts: Data and Statistics about Diabetes, revised 7/2014. Available from: http://professional. diabetes.org/admin/UserFiles/0%20-%20 Sean/14-fast-facts-june2014-final3.pdf. Accessed January 12, 2015.
3. Gregg EW, Zhuo X, Cheng YJ, Albright AL, Narayan KM, Thompson TJ. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study. Lancet Diabetes Endocrinol. 2014;2(11):867-874. http://dx.doi.org/10.1016/S2213-8587(14)70161-5. PMID:25128274.
4. Drug Store News. Johnsen M. Survey: Latinos see diabetes as biggest health concern for their families, January 22, 2014. Available from: http://www.drugstorenews.com/article/surveylatinos-see-diabetes-biggest-health-concerntheir-families. Accessed January 12, 2015.
5. Hunt KJ, Williams K, Resendez RG, Hazuda HP, Haffner SM, Stern MP. All-cause and cardiovascular mortality among diabetic participants in the San Antonio Heart Study: evidence against the "Hispanic Paradox". Diabetes Care. 2002;25(9):1557-1563. http:// dx.doi.org/10.2337/diacare.25.9.1557. PMID:12196427.
6. Caballero AE. Type 2 diabetes in the Hispanic or Latino population: challenges and opportunities. Curr Opin Endocrinol Diabetes Obes. 2007;14(2):151-157. http://dx.doi. org/10.1097/MED.0b013e32809f9531. PMID:17940434.
7. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053. http:// dx.doi.org/10.2337/diacare.27.5.1047. PMID:15111519.
8. Boltri JM, Okosun IS, Davis-Smith M, Vogel RL. Hemoglobin A1c levels in diagnosed and undiagnosed black, Hispanic, and white persons with diabetes: results from NHANES 1999-2000. Ethn Dis. 2005;15(4):562-567. PMID:16259477.
9. Lopez JM, Bailey RA, Rupnow MF, Annunziata K. Characterization of type 2 diabetes mellitus burden by age and ethnic groups based on a nationwide survey. Clin Ther. 2014;36(4):494-506. http://dx.doi. org/10.1016/j.clinthera.2013.12.016. PMID:24508418.
10. Ferrannini E, Gastaldelli A, Matsuda M, et al. Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. J Clin Endocrinol Metab. 2003;88(7):3251-3257. http://dx.doi.org/10.1210/jc.2002-021864. PMID:12843172.
11. Lorenzo C, Hazuda HP, Haffner SM. Insulin resistance and excess risk of diabetes in Mexican-Americans: the San Antonio Heart Study. J Clin Endocrinol Metab. 2012;97(3):793-799. http://dx.doi.org/10.1210/jc.2011-2272. PMID:22174423.
12. Campos C. Addressing cultural barriers to the successful use of insulin in Hispanics with type 2 diabetes. South Med J. 2007;100(8):812-820. http://dx.doi.org/10.1097/ SMJ.0b013e3180f609c4. PMID:17713308.
13. Davidson JA, Lacaya LB, Jiang H, et al. Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocr Pract. 2010;16(5):818-828. http://dx.doi.org/10.4158/EP09285.OR. PMID:20439249.
14. Zeitler P, Hirst K, Pyle L, et al; TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247-2256. http://dx.doi.org/10.1056/NEJMoa1109333. PMID:22540912.
15. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucoselowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696-708. http:// dx.doi.org/10.1007/s00125-012-2827-3. PMID:23344728.
16. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375-393. http://dx.doi.org/10.310 9/07853890.2011.560181. PMID:21495788.
17. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453-467. PMID:24348059.
18. Matthews D, Zinman B, Tong C, Meininger G, Polidori D. Glycemic efficacy of canagliflozin (CANA) is largely independent of baseline beta-cell function or insulin sensitivity. [abstract 1096-P]. Diabetes. 2014;63(suppl 1):A285.
19. American Diabetes Association. Standards of Medical Care in Diabetes. (7) Approaches to Glycemic Treatment. Diabetes Care. 2015;38(suppl 1):S41-S48. http://dx.doi. org/10.2337/dc15-S010. PMID:25537707.
20. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382. http://dx.doi. org/10.1111/dom.12054. PMID:23279307.
21. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582-2592. http:// dx.doi.org/10.1007/s00125-013-3039-1. PMID:24026211.
22. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267-1282. http://dx.doi. org/10.1111/ijcp.12322. PMID:24118688.
23. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467-477. http://dx.doi. org/10.1111/dom.12273. PMID:24528605.
24. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-950. http:// dx.doi.org/10.1016/S0140-6736(13)60683-2. PMID:23850055.
25. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-2022. http://dx.doi. org/10.2337/dc11-0606. PMID:21816980.
26. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262-274. http://dx.doi.org/10.7326/0003-4819-159-4-201308200-00007. PMID:24026259.
27. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig. 2014;4;5(3):265-75.
28. Rodriguez CJ, Daviglus ML, Swett K, et al. Dyslipidemia patterns among Hispanics/Latinos of diverse background in the United States. Am J Med. 2014;127(12):1186-94.e1. http:// dx.doi.org/10.1016/j.amjmed.2014.07.026. PMID:25195188.
29. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126(3):16-34. http://dx.doi.org/10.3810/pgm.2014.05.2753. PMID:24918789.
30. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2013;125(3):33-46. http://dx.doi.org/10.3810/ pgm.2013.05.2650. PMID:23748505.